

Antibiotic Resistance: Current Practices and Strategies to Overcome this Growing Threat

<https://marketpublishers.com/r/A64D2A3B53CEN.html>

Date: January 2015

Pages: 320

Price: US\$ 5,950.00 (Single User License)

ID: A64D2A3B53CEN

Abstracts

Biopharm Reports has carried two comprehensive market studies, covering bacterial molecular diagnostics and antibiotic resistance. These studies involved the participation of 1072 experienced researchers, clinicians and laboratory end-users and profiled current practices, developments, trends and plans over the next three years, as well as growth and opportunities across key sectors of these markets. These findings provide a wealth of market information on the current and evolving markets for bacterial molecular diagnostics and antibiotic resistance.

BACTERIAL MOLECULAR DIAGNOSTICS

This study profiled 420 experienced clinicians and research scientists and investigated current practices, developments, trends and future plans over the next three years, as well as growth, shrinkage and opportunities across key areas of this market. Its findings provide suppliers with market information on the current and evolving use of bacterial molecular diagnostics. The study investigated 45 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on the current and evolving use of bacterial molecular diagnostics and assist companies selling into these markets to respond to laboratory users' current needs and their future plans.

Market studies carried out by Biopharm Reports are designed to assist laboratory suppliers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user needs, our studies assist suppliers to sell into these markets, and support innovation, development and strategic planning.

ANTIBIOTIC RESISTANCE

Market findings from this study are based on 'real world' laboratory data, provided by research scientists and clinicians who work routinely on the challenges posed by antibiotic resistance.

This study investigated 117 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on current and developing activities to combat antibiotic resistance and assist companies selling into these markets to respond to laboratory users' current needs and their future plans.

Biopharm Reports specialises in carrying out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years. The associated report provides a competitive market analysis of current practices and future developments across 25 key areas relating to antibiotic resistance. Examples include:

Diagnostics: Therapeutic areas, top Gram positives, Gram negatives and other pathogens; current and future development of companion diagnostics, tests to distinguish between bacterial and viral infections, the identification of causal bacterial pathogens, bacterial identification methods, preferred tests and instrumentation, preferred suppliers, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives and barriers to success.

Clinical: Therapeutic areas, top infection types, the major Gram positives, Gram negatives and other pathogens; distinguishing bacterial and viral infections, test costs and test times per patient, the identification of causal bacterial, preferred methods and suppliers, the identification of antibiotic resistance genes, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives, barriers to success and future plans in these areas

Suppliers: Who are the major company suppliers in the 'antibiotic resistance' market and who do diagnosticians and clinicians plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes

are predicted in three years from now.

Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the 'antibiotic resistance' market, in each of the 'Diagnostics', 'Clinical' and 'Laboratory' areas indicated below.

Contents

1. GENERAL

- 1.1 Study description
- 1.2 Participants
- 1.3 Countries
- 1.4 organisations

2. CLINICAL

- 2.1 Top Therapeutic Areas
- 2.2 Top Infection Types
- 2.3 Differentiating Bacterial and Viral Infections
 - 2.3.1 Current patients
 - 2.3.2 Preferred distinguishing tests
 - 2.3.3 Suppliers and instrumentation
 - 2.3.4 Test costs per patient
 - 2.3.5 Test time
 - 2.3.6 Future distinction between bacterial and viral infections
 - 2.3.7 Future patients
 - 2.3.8 Future tests and instrumentation
 - 2.3.9 Future preferred suppliers
- 2.4 Causal Bacteria
 - 2.4.1 Identification methods
 - 2.4.2 Current patients
 - 2.4.3 Laboratory identification methods
 - 2.4.4 Preferred tests and instrumentation
 - 2.4.5 Preferred suppliers
 - 2.4.6 Test costs per patient
 - 2.4.7 Test time
 - 2.4.8 Future identification of causal bacterial types
 - 2.4.9 Future patients
 - 2.4.10 Future bacterial identification methods
 - 2.4.11 Tests and instrumentation
 - 2.4.12 Preferred suppliers
- 2.5 Antibiotic Resistance Genes
 - 2.5.1 Current patients
 - 2.5.2 Preferred tests and instrumentation

- 2.5.3 Preferred suppliers
- 2.5.4 Testing costs
- 2.5.5 Test time
- 2.5.6 Future identification of resistance genes
- 2.5.7 Future patients
- 2.5.8 Antibiotic resistance gene tests and instrumentation
- 2.5.9 Future suppliers
- 2.6 Integrated Programmes
 - 2.6.1 Current programmes
 - 2.6.2 Names and locations
 - 2.6.3 Future programmes
 - 2.6.4 Names and locations
- 2.7 Antimicrobial stewardship programmes
 - 2.7.1 Current programmes
 - 2.7.2 Names and locations
 - 2.7.3 Future programmes
 - 2.7.4 Names and locations
 - 2.7.5 Future antimicrobial stewardship programmes
 - 2.7.6 Name and location
- 2.8 Gram negative bacteria
- 2.9 Gram positive bacteria
- 2.10 Other bacteria
- 2.11 Antibiotics against Gram negative bacteria
- 2.12 Antibiotics against Gram positive bacteria
- 2.13 Antibiotics against other bacteria
- 2.14 Treatment costs
- 2.15 Single antibiotics or combinations
- 2.16 Innovation
- 2.17 Barriers
- 2.18 Initiatives

3. LABORATORY

- 3.1 Purpose
- 3.2 Top three therapeutic areas
- 3.3 Antibiotic source
- 3.4 Gram negative bacteria
- 3.5 Gram positive bacteria
- 3.6 Other bacteria

- 3.7 Companion diagnostics
- 3.8 Current Identification methods
 - 3.8.1 Preferred current products and suppliers
- 3.9 Future identification methods
 - 3.9.1 Preferred products and supplier
- 3.10 Antibiotics against Gram negative bacteria
- 3.11 Antibiotics against Gram positive bacteria
- 3.12 Antibiotics against other bacteria
- 3.13 Novel antibiotic combinations
- 3.14 Single antibiotics or combinations
- 3.15 Integrated programmes
 - 3.15.1 Current programmes
 - 3.15.2 Names and locations
 - 3.15.3 Future programmes
 - 3.15.4 Names and locations
- 3.16 Current programme
- 3.17 Future integrated programme
- 3.18 Name and location
- 3.19 Antimicrobial stewardship programmes
 - 3.19.1 Current programmes
 - 3.19.2 Names and locations
 - 3.19.3 Future programmes
 - 3.19.4 Names and locations
- 3.20 Innovation
- 3.21 Barriers
- 3.22 Initiatives

4. DIAGNOSTICS

- 4.1 Therapeutic areas
- 4.2 Source of antibiotics
- 4.3 Gram negative bacteria
- 4.4 Gram positive bacteria
- 4.5 Other bacteria
- 4.6 Companion diagnostics
- 4.7 Bacterial and viral infections
- 4.8 Future tests for distinguishing bacterial and viral infections
- 4.9 Identifying causal bacteria
- 4.10 laboratory identification methods

- 4.10.1 Preferred products and suppliers
- 4.11 Future identification of causal bacterial types
 - 4.11.1 Preferred products and suppliers
- 4.12 Integrated programmes
 - 4.12.1 Current programmes
 - 4.12.2 Names and locations
 - 4.12.3 Future programmes
 - 4.12.4 Names and locations
- 4.13 Antimicrobial stewardship programmes
 - 4.13.1 Current programmes
 - 4.13.2 Names and locations
 - 4.13.3 Future programmes
 - 4.13.4 Names and locations
- 4.14 Innovation
- 4.15 Barriers
- 4.16 Initiatives

BACTERIAL MOLECULAR DIAGNOSTICS

1. INTRODUCTION

- 1.1. Market Questions
- 1.2. Discussion

2. PARTICIPANTS

- 2.1 Global Regions
- 2.2 Countries
- 2.3 Job Title
- 2.4 Experience
- 2.5 Organisation Type
- 2.6 Field
- 2.7 Purpose
- 2.8 Role
- 2.9 Main Activity
- 2.10 Discussion

3. ASSOCIATED THERAPEUTIC AREAS

- 3.1. Associated Therapeutic Areas
- 3.2 Market Questions
- 3.3 Other Therapeutic Areas
- 3.4. Discussion

4. BACTERIA

- 4.1 Market Questions
- 4.2 Current Gram Negative Bacteria
- 4.3 Future Gram Negative Bacteria
- 4.4 Current Gram Positive Bacteria
- 4.5 Future Gram Positive Bacteria
- 4.6 Current Other Bacteria
- 4.7 Future Other Bacteria
- 4.8 Discussion

5 MAIN BACTERIAL TESTS

- 5.1. Main Bacterial Tests
- 5.2 Market Questions
- 5.3 Current Bacterial Tests
- 5.4 Other Current Bacterial Tests
- 5.5 Future Bacterial Tests
- 5.6 Other Future Bacterial Tests
- 5.7 Discussion

6 SAMPLES

- 6.1 Samples
- 6.2 Market Question
- 6.3. Samples
- 6.4. Discussion

7 BACTERIAL MOLECULAR TECHNIQUES

- 7.1 Bacterial Molecular Techniques
- 7.2 Market Questions
- 7.3 Current Molecular Techniques
- 7.4 Other Current Molecular Techniques

- 7.5 Future Molecular Techniques
- 7.6 Other Future Molecular Techniques
- 7.7 Discussion

8 MAIN BACTERIAL TESTED

- 8.1 Main Bacteria Tested
- 8.2 Market Questions
- 8.3 Current Gram Negative Bacteria
- 8.4 Future Gram Negative Bacteria
- 8.5 Current Main Gram Positive Bacteria
- 8.6 Future Gram Positive Bacteria
- 8.7. Current Other Bacteria
- 8.8 Future Other Bacteria
- 8.9 Discussion

9 BACTERIA TESTED SIMULTANEOUSLY

- 9.1 Bacteria Tested Simultaneously
- 9.2 Market Question
- 9.3 Current Bacteria Tested Simultaneously
- 9.4 Future Bacteria Tested Simultaneously
- 9.5 Discussion

10 MULTIPLEX METHODS

- 10.1 Multiplex Methods
- 10.2 Market Questions
- 10.3 Current Multiplex Methods
- 10.4 Future Multiplex Methods
- 10.5 Discussion

11 BACTERIAL MOLECULAR DIAGNOSTIC TRENDS

- 11.1 Bacterial Molecular Diagnostic Trends
- 11.2 Market Questions
- 11.3 Recent Trends
- 11.4 Future Trends
- 11.5 Discussion

12 APPLICATIONS

- 12.1 Applications
- 12.2 Market Questions
- 12.3 Current Main Applications
- 12.4 Other Current Applications
- 12.5 Future Applications
- 12.6 Other Future Applications
- 12.7 Discussion

13 SUPPLIERS

- 13.1 Suppliers
- 13.2 Market Questions
- 13.3 Current Suppliers
- 13.4 Other Current Suppliers
- 13.5 Future Suppliers
- 13.6 Other Future Suppliers
- 13.7 Discussion

14 ADVANTAGES AND DISADVANTAGES

- 14.1 Advantages and Disadvantages
- 14.2 Market Questions
- 14.3 Advantages
- 14.4 Other Advantages
- 14.5 Disadvantages
- 14.6 Other Disadvantages
- 14.7 Discussion

15 FUTURE IMPROVEMENTS

- 15.1 Future Improvements
- 15.2 Market Questions
- 15.3 Future Improvements
- 15.4 Other Future Improvements
- 15.5 Discussion

16 TECHNIQUE REPLACEMENT

- 16.1 Technique Replacement
- 16.2 Market Questions
- 16.3 Technique Replacement
- 16.4 Other Technique Replacement
- 16.5 Discussion

17 AUTOMATION

- 17.1 Automation
- 17.2 Market Questions
- 17.3 Current Automation
- 17.4 Preferred Automation Suppliers
- 17.5 Discussion

18 MOST TESTED BACTERIA

- 18.1 Most Tested Bacteria
- 18.2 Market Questions
- 18.3 Most Tested Bacteria
- 18.4 Costs
- 18.5 Budget
- 18.6 Preferred Suppliers
- 18.7 Other Preferred Suppliers
- 18.8 Discussion

19 DISCUSSION

Figures

FIGURES

Figure 2.1. Global regions of participants in BMD

Figure 2.2. Countries of participants in BMD

Figure 2.3. Job titles of participants in BMD

Figure 2.4. Bacterial diagnostics experience of participants in BMD

Figure 2.5. Organisations of participants in BMD

Figure 2.6. Fields of participants in BMD

Figure 2.7. Purpose of Bacterial diagnostics activities of participants in BMD4

Figure 2.8. Role of participants in BMD

Figure 2.9. Main activity of participants in BMD

Figure 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics

Figure 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD

Figure 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Figure 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD

Figure 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Figure 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD

Figure 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Figure 5.2. Main types of bacterial tests currently used, indicated by participants in BMD

Figure 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD

Figure 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD

Figure 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD

Figure 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD

Figure 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Figure 8.4. Main Gram negative bacteria anticipated to be tested for in three years from

now, indicated by participants in BMD

Figure 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Figure 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD

Figure 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Figure 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD

Figure 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD

Figure 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD

Figure 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD

Figure 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD

Figure 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD

Figure 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD

Figure 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BM

Figure 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD

Figure 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD

Figure 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD

Figure 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD

Figure 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD

Figure 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD

Figure 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD

Figure 17.2. Percentage of end-users bacterial molecular diagnostics that are

automated, indicated by participants in BMD

Figure 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD

Figure 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD

Figure 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD

Figure 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD

Tables

TABLES

Table 2.1. Global regions of participants in BMD

Table 2.2. Countries of participants in BMD

Table 2.3. Job titles of participants in BMD

Table 2.4. Bacterial diagnostics experience of participants in BMD

Table 2.5. Organisations of participants in BMD

Table 2.6. Fields of participants in BMD

Table 2.7. Purpose of Bacterial diagnostics activities of participants in BMD

Table 2.8. Pole of participants in BMD

Table 2.9. Main activity of participants in BMD

Table 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics

Table 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD

Table 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Table 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD

Table 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Table 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD

Table 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD

Table 5.2. Main types of bacterial tests currently used, indicated by participants in BMD

Table 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD

Table 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD

Table 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD

Table 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD

Table 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Table 8.4. Main Gram negative bacteria anticipated to be tested for in three years from

now, indicated by participants in BMD

Table 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Table 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD

Table 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD

Table 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD

Table 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD

Table 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD

Table 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD

Table 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD

Table 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD

Table 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD

Table 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BMD

Table 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD

Table 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD

Table 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD

Table 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD

Table 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD

Table 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD

Table 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD

Table 17.2. Percentage of end-users bacterial molecular diagnostics that are

automated, indicated by participants in BMD

Table 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD

Table 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD

Table 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests indicated referred to, indicated by participants in BMD

Table 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD

I would like to order

Product name: Antibiotic Resistance: Current Practices and Strategies to Overcome this Growing Threat

Product link: <https://marketpublishers.com/r/A64D2A3B53CEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A64D2A3B53CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970